PATENT CLAIM ANALYSIS

Application Number: 16268373
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-08
Patent Classification: ["514", "662000"]

Abstract:
The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

Claim (Index 25):
The solid oral dosage form of  claim 1 , wherein the dosage form is a tablet.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 99.0
- Lexical Diversity: 1.26087
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16250686', '16250608', '16241636', '16241631', '15898143']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8774400868982901
- 35 USC 102 Novelty (BERT): 0.6534857254494831
- Combined Prediction Score: 0.8550446507534094
- Mean Citation Score: 583.1418300000001
- Max Citation Score: 596.4094
- Similarity Product: 414.9020706338405

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test